Insofar management for thrombocytopenias associated with RUNX1, ANKRD26, or ETV6 mutations are concerned, a cytogenetic bone marrow examination is recommende at the time of diagnosis, particularly if the mutations have already been reported and have proven pathogenicity. The gene discussed is ANKRD26; the disease is Thrombocytopenia.